United Health Products Provides Update on FDA PMA Application
United Health Products Provides Update on FDA PMA Application
Mesquite, NV, Nov. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- United Health Products, Inc. (OTCPK: UEEC), (UHP) today provides an update on the company's FDA Premarket Approval application.
梅斯基特，內華達州，2022 年 11 月 28 日（環球美通社）-通過新媒體 --聯合健康產品有限公司（OTCPK：UEEC），（UHP）今天提供有關該公司 FDA 市前批准申請的最新信息。
UHP continues to advance its Premarket Approval application with the Food and Drug Administration. As described in its October 31 press release, the company has completed its review and documentation of manufacturing and packaging related Standard Operating Procedures (SOPs) and is now awaiting external laboratory test results on HemoStyp samples produced under its new manufacturing arrangement. Upon receipt and review of the sample analysis, the company expects to submit its full PMA application within a few days. There can be no assurance that the company's PMA application will be approved.
UHP 繼續向美國食品藥物管理局推進其上市前批准申請。正如 10 月 31 日新聞稿中所述，該公司已完成與製造和包裝相關的標準操作程序（SOP）的審查和文件，目前正等待根據其新製造安排生產的 HemoStyp 樣品進行外部實驗室 test 結果。在收到並審查樣本分析後，該公司預計在幾天內提交完整的 PMA 申請。不能保證公司的 PMA 申請將獲得批准。
About United Health Products -- UHP develops, manufactures and markets HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and emergency medicine markets, and is focused on gaining approval to access the human surgical market.
關於聯合健康產品-UHP 開發，製造和銷售專利的中和氧化再生纖維素（NORC）止血劑 HemoStyp™。HemoStyp 是一種全天然產品，旨在控制出血。UHP 目前為牙科，獸醫和急診醫學市場提供了一套止血產品，並致力於獲得進入人類外科市場的批准。
For more information on UHP visit the company's new website: or contact the company at info@uhpcorp.com.
有關 UHP 的更多信息，請訪問該公司的新網站：或通過 info@uhpcorp.com 與公司聯繫。
The company can also be reached by phone or text message at 475.755.1005.
該公司也可以通過電話或短信聯繫到 475.755.1005。
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
根據 1995 年《私人證券訴訟改革法》的安全港聲明：此新聞稿可能包含 1933 年證券法第 27A 條所指的前瞻性信息，以及經修訂的 1934 年證券交易法第 21E 條的前瞻性信息，包括包括「相信」，「期望」，「預期」或類似表達的聲明。該等前瞻性陳述涉及已知及未知的風險、不明朗因素及其他因素，這些因素可能導致公司的實際業績、表現或成就與該等前瞻性陳述所明示或暗示的有重大差異。
譯文內容由第三人軟體翻譯。